U.S. Markets closed

Liquidia Corporation (LQDA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.6800+0.0300 (+1.13%)
At close: 4:00PM EDT
2.7300 +0.05 (1.87%)
After hours: 05:34PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.6500
Open2.6600
Bid2.6800 x 1300
Ask2.6700 x 1800
Day's Range2.6100 - 2.7100
52 Week Range2.3400 - 12.1000
Volume373,513
Avg. Volume559,346
Market Cap139.288M
Beta (5Y Monthly)0.06
PE Ratio (TTM)N/A
EPS (TTM)-1.7640
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.25
  • United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia
    PR Newswire

    United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia

    United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc. (a subsidiary of Liquidia Corporation, Nasdaq: LQDA) and a former United Therapeutics employee who later joined Liquidia as an executive. The claims allege that Liquidia conspired with the former employee to misappropriate United Therapeutics' trade secrets, including regulatory submissions and detailed financial forecasts, in

  • Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder
    GlobeNewswire

    Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder

    MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for LIQ861 (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH). The FDA confirmed that the resubmission was a complete, class 2 response to the previous action letter issued on November 24, 2020. The FDA set a PDUFA goal date of November 7, 2021. If the FDA det

  • Liquidia Corporation To Present At The Jefferies Virtual Healthcare Conference
    GlobeNewswire

    Liquidia Corporation To Present At The Jefferies Virtual Healthcare Conference

    MORRISVILLE, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual Healthcare Conference. The presentation will take place on Wednesday, June 2, 2021, from 2:30 to 2:55 p.m. Eastern Daylight Time and can be accessed via a live webcast on the Liquidia website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the presentation can be accessed for 90 days following the event. About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies is developing LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com. Contact InformationMedia & Investors:Jason AdairVice President, Corporate Development and Strategy919.328.4400jason.adair@liquidia.com